Enzalutamide Tablets: Redefining Prostate Cancer Care in the Era of Oral Precision Oncology

Enzalutamide has emerged as a cornerstone in metastatic castration-resistant prostate cancer, delivered as an oral tablet that aligns with today's emphasis on patient-centric, home-based therapy. By antagonizing the androgen receptor, it interrupts the signaling axis that fuels tumor growth, delivering meaningful survival benefits when used in appropriate lines of therapy. The shift from intravenous options to a potent oral option has streamlined workflows, reduced clinic visits, and empowered patients to maintain quality of life while pursuing disease control.

From a decision-making perspective, patient selection and sequencing remain critical. Enzalutamide is typically positioned after progression on androgen-deprivation therapy, and its use must consider comorbidities, seizure risk, and potential drug interactions with concomitant therapies. Real-world data increasingly inform tailoring-balancing efficacy with tolerability, monitoring blood pressure, liver function, and cognitive effects, and integrating supportive care to manage fatigue and falls risk. Payer perspectives focus on value: demonstrating survival benefit, symptom relief, and the ability to sustain home-based care without hospitalizations.

Looking forward, the trend is toward personalized strategies that combine sequencing insights with biomarkers and digital health tools to monitor response and adherence. Enzalutamide's role extends beyond single-agent use as investigators explore combinations and optimized regimens that delay resistance and maximize patient well-being. For decision-makers, the message is clear: invest in robust patient support, rigorous real-world evidence, and interoperable data systems that capture outcomes across settings to unlock continued value from this oral precision therapy.